Skip to main content
Top
Published in: Breast Cancer 2/2011

01-04-2011 | Special Feature

Preoperative therapy: recent findings

Author: Takayuki Kinoshita

Published in: Breast Cancer | Issue 2/2011

Login to get access

Abstract

Preoperative systemic therapy (PST) is the standard treatment for locally advanced breast cancer and a standard option for primary operable breast cancer. PST for breast cancer is as effective as postoperative adjuvant therapy, which permits more lumpectomies and can be used to study breast cancer biology. For locally advanced breast cancer patients, the primary aim of PST is to improve surgical option. For operable breast cancer patients, the primary aim of PST is to obtain freedom from disease. Because of recent advances in treatment and our understanding of the disease, we summarized the current consensus on the adoption and benefits of PST, especially for operable breast cancer patients.
Literature
1.
go back to reference Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;8:2672–85. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;8:2672–85.
2.
go back to reference Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: 9-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102.PubMed Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: 9-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102.PubMed
3.
go back to reference Van der Huge JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224–37. Van der Huge JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224–37.
4.
go back to reference Kaufmann M, Hortobagi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendation from an international expert panel on the use of neoadjuvant systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–9.PubMedCrossRef Kaufmann M, Hortobagi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendation from an international expert panel on the use of neoadjuvant systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–9.PubMedCrossRef
5.
go back to reference Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;15:1456–66.CrossRef Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;15:1456–66.CrossRef
6.
go back to reference Semiglazov, VF, Semiglazov, VV, Berstein LM (2003) In: Proceedings of SABC (abstract). Semiglazov, VF, Semiglazov, VV, Berstein LM (2003) In: Proceedings of SABC (abstract).
Metadata
Title
Preoperative therapy: recent findings
Author
Takayuki Kinoshita
Publication date
01-04-2011
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2011
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-010-0227-4

Other articles of this Issue 2/2011

Breast Cancer 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine